Efgartigimod has efficacy superior to placebo for generalized myasthenia gravis

• Posted on: Apr 14 2022
• By: Saratoga Opthalmology
• Leave a response

Results from the phase 3 ADAPT trial of the efficacy and safety of efgartigimod in patients with generalized myasthenia gravis (MG) are now available.
Source: AAO

Posted in: Uncategorized